Back to Journals » Drug Design, Development and Therapy » Volume 13

Effect of butorphanol on etomidate-induced myoclonus: a systematic review and meta-analysis

Authors Hua J, Miao S, Shi M, Tu Q, Wang X, Liu S, Wang G, Gan J

Received 1 November 2018

Accepted for publication 23 March 2019

Published 16 April 2019 Volume 2019:13 Pages 1213—1220

DOI https://doi.org/10.2147/DDDT.S191982

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Cristiana Tanase


Jun Hua,1 Shuai Miao,2 Mengzhu Shi,2 Qing Tu,3 Xiuli Wang,2 Su Liu,2 Guanglei Wang,2 Jianhui Gan3

1Department of Anesthesiology, The 101 Hospital of Chinese People’s Libration Army, Wuxi, Jiangsu, People’s Republic of China; 2Department of Anesthesiology, The Affiliated Hospital of XuZhou Medical University, Xuzhou, Jiangsu, People’s Republic of China; 3Department of Anesthesiology, Tangshan People‘s Hospital, North China University of Science and Technology, Tangshan, Hebei, People’s Republic of China

Objective: To evaluate the effect of butorphanol on the prevention of myoclonus induced by etomidate.
Materials and methods: We searched the PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure databases to collect relevant randomized controlled trials (RCTs) evaluating the effect of butorphanol on etomidate-induced myoclonus in January 2019 without any language restrictions. The primary outcome was the incidence of etomidate-induced myoclonus. Secondary outcomes included the incidence of myoclonus at various degrees and the incidence of adverse effects. Risk ratios (RRs) were calculated for binary outcomes. All statistical analysis were performed by using RevMan 5.3 software.
Results: We identified 6 RCTs involving a total of 608 patients who reported the incidence of etomidate-induced myoclonus. In pooled analyses, the incidence of etomidate-induced myoclonus in the butorphanol group was significantly lower than that in the control group (RR =0.15, 95% CI [0.10, 0.22], P<0.00001). Subgroup analyses showed that butorphanol significantly decreased the numbers of patients with mild myoclonus (RR =0.41, 95% CI [0.25, 0.68], P=0.0005), moderate myoclonus (RR =0.18, 95% CI [0.09, 0.34], P<0.00001), and severe myoclonus (RR =0.04, 95% CI [0.01, 0.10], P<0.00001). Additionally, butorphanol did not increase the incidence of postoperative nausea/vomiting (RR =3.0, 95% CI [0.32, 28.42], P=0.34) or dizziness (RR =6.79, 95% CI [0.84, 54.84], P=0.07) associated with etomidate.
Conclusion: Our findings suggest that butorphanol can effectively prevent the incidence of etomidate-induced myoclonus and alleviate the intensity of etomidate-induced myoclonus, without inducing postoperative nausea/vomiting and dizziness.

Keywords: butorphanol, etomidate, myoclonus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]